Drug class
Long-acting parathyroid hormone (PTH 1-34) prodrug conjugate; PTH replacement therapy
Mechanism of action
Palopegteriparatide is a prodrug that releases active PTH(1-34) under physiological conditions, providing sustained PTH exposure. PTH receptor activation regulates renal calcium reabsorption, phosphate excretion and vitamin D activation, restoring calcium-phosphate homeostasis.
General use cases
- Treatment of hypoparathyroidism in adults under the US YORVIPATH indication; it was not studied for acute post-surgical hypoparathyroidism and requires calcium-guided titration
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
